Nutriband Completes Strategic Divestment: $5 Million Deal Transfers Pocono Pharma Stake To EarthVision Bio

robot
Abstract generation in progress

Nutriband Inc. (NTRB) has finalized a major portfolio transaction, transferring a 90% ownership stake in its subsidiary Pocono Pharmaceutical to EarthVision Bio in exchange for $5 million. The move represents a strategic pivot focused on prioritizing core product development.

The Acquirer’s Track Record

EarthVision Bio brings substantial credentials to the transaction. The company specializes in developing sustainable alternatives to conventional materials, with backing from notable figures including Dr. Gordon Moore, Intel’s founder, and Dr. Hans Franke, former board chairman of Chevron Europe. Their mission centers on replacing plastic, molded fiber, wood, and paper products with environmentally-conscious substitutes.

Capital Allocation and Shareholder Position

Following the transaction, Nutriband shareholders will maintain a 10% stake in EarthVision Bio, preserving ongoing exposure to the acquirer’s growth trajectory. The $5 million proceeds from this divestment will be redirected toward accelerating development of AVERSA Fentanyl, the company’s flagship pharmaceutical asset.

AVERSA Fentanyl: Positioning For Market Dominance

AVERSA Fentanyl represents Nutriband’s concentrated bet on the abuse-deterrent opioid space. The transdermal patch technology is engineered to resist tampering and misuse while minimizing accidental exposure risks—positioning it as a potential first-to-market solution with these integrated safeguards. Market projections suggest the product could capture $80 million to $200 million in annual US revenues at peak adoption, underscoring the strategic importance of this capital reallocation.

The transaction underscores how biotech companies are increasingly streamlining portfolios to concentrate resources on high-potential pipeline assets with substantial commercial runway.

Disclaimer: The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)